JIANGSU KANION PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.92 CNY | +1.39% |
|
-10.92% | -7.80% |
| Sales 2024 * | 5.79B 799M | Sales 2025 * | 6.69B 923M | Capitalization | 11.05B 1.53B |
|---|---|---|---|---|---|
| Net income 2024 * | 657M 90.75M | Net income 2025 * | 779M 108M | EV / Sales 2024 * | 1.91 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.65 x |
| P/E ratio 2024 * |
16.9
x | P/E ratio 2025 * |
14.2
x | Employees | - |
| Yield 2024 * |
2.22% | Yield 2025 * |
2.59% | Free-Float | 58.15% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.39% | ||
| 1 week | -10.92% | ||
| Current month | -8.78% | ||
| 1 month | -16.98% | ||
| 3 months | -1.25% | ||
| 6 months | +14.88% | ||
| Current year | -7.80% |
1 week
18.03
19.71
1 month
18.0322.75
Current year
13.3624.09
1 year
13.3632.25
3 years
9.2233.71
5 years
8.4033.71
10 years
8.2434.32
| Managers | Title | Age | Since |
|---|---|---|---|
Yong Chun Yang
CEO | Chief Executive Officer | 51 | 96-12-31 |
Suo Cheng Jiang
DFI | Director of Finance/CFO | 47 | 00-11-30 |
Wei Xiao
CHM | Chairman | 65 | 00-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wei Xiao
CHM | Chairman | 65 | 00-11-30 |
Kai Xian Chen
BRD | Director/Board Member | 79 | 19-12-26 |
Yong Chun Yang
CEO | Chief Executive Officer | 51 | 96-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +1.25% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 18.92 | +1.39% | 7,944,600 |
| 24-04-18 | 18.66 | -0.85% | 10,740,400 |
| 24-04-17 | 18.82 | +1.84% | 17,883,610 |
| 24-04-16 | 18.48 | -3.35% | 33,642,430 |
| 24-04-15 | 19.12 | -9.98% | 10,110,700 |
End-of-day quote Shanghai S.E., April 18, 2024
More quotes
Jiangsu Kanion Pharmaceutical Co., Ltd. is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals. The Company provides capsules, oral liquid, granules, electuary, tablets, pills, patch and injections. The Company's products are applied in gynecology, orthopedics, cardiovascular and cerebrovascular, anti-infective, anti-tumor and others. The Company distributes its products mainly within domestic markets.
Sector
Pharmaceuticals
Calendar
2024-08-20
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
18.92
CNY
Average target price
25.17
CNY
Spread / Average Target
+33.05%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -7.80% | 1.51B | |
| +24.60% | 672B | |
| +24.08% | 550B | |
| -5.63% | 351B | |
| +15.37% | 317B | |
| +7.38% | 292B | |
| +3.26% | 211B | |
| +0.78% | 203B | |
| -9.69% | 144B | |
| -6.63% | 141B |
- Stock Market
- Equities
- 600557 Stock
